Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Completed · Phase 2
Conditions studied: Breast Neoplasms
In brief
This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.
Key facts
- Study ID
- NCT01670877
- Run by
- Washington University School of Medicine
- People needed
- 56
- Starts
- 2012-12-11
- Expected to finish
- 2021-03-11
- Last updated by the study team
- 2022-04-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama Cancer Center — Birmingham, Alabama, United States
- Mayo Clinic — Phoenix, Arizona, United States
- University of Southern California Keck School of Medicine — Los Angeles, California, United States
- Stanford Medicine Cancer Institute — Stanford, California, United States
- University of Miami Hospital and Clinics — Miami, Florida, United States
- Northwestern University - Feinberg School of Medicine — Chicago, Illinois, United States
- Rush University Medical Center — Chicago, Illinois, United States
- Dana-Farber Cancer Institute, Harvard University — Boston, Massachusetts, United States
- University of Michigan — Ann Arbor, Michigan, United States
- St. Luke's Cancer Institute — Kansas City, Missouri, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- University of North Carolina at Chapel Hill (Lineberger Comprehensive Cancer Center) — Chapel Hill, North Carolina, United States
- Duke Cancer Institute at Duke University Medical Center — Durham, North Carolina, United States
- Avera Cancer Institute — Sioux Falls, South Dakota, United States
- Baylor College of Medicine — Houston, Texas, United States
- BC Cancer Agency — Vancouver, British Columbia, Canada
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.